Wall Street analyst estimates for Ocugen, Inc. (OCGN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.06 | ||
| 2026-08-06 | $-0.07 | $-0.05 | -31.3% |
| 2026-05-05 | $-0.06 | $-0.05 | -20.0% |
| 2026-03-04 | $-0.06 | $-0.06 | +0.0% |
| 2025-11-05 | $-0.07 | $-0.06 | -21.7% |
| 2025-08-01 | $-0.05 | $-0.06 | +16.7% |
| 2025-05-09 | $-0.05 | $-0.06 | +16.7% |
| 2025-03-05 | $-0.05 | $-0.05 | +0.0% |
Valuation Ratios
| Price / Book | -20.88 |
| EV / EBITDA | -6.40 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $43000 | 0 | $2.5M | $6.0M | $4.1M | $4.4M |
| Cost of Revenue | $1.7M | $1.5M | $49623 | $8.1M | $6.4M | 0 | 0 | $704000 | $2.0M | $2.4M |
| Gross Profit | -$1.7M | -$1.5M | -$49623 | -$8.1M | -$6.3M | 0 | $2.5M | $5.3M | $2.1M | $2.0M |
| Research & Development | $21.6M | $15.6M | $15.6M | $8.1M | $13.4M | $35.1M | $56.2M | $39.6M | $32.1M | $39.8M |
| Selling, General & Admin | $8.5M | $9.4M | $10.2M | $6.1M | $8.0M | $22.9M | $35.4M | $32.0M | $26.7M | $27.6M |
| Operating Expenses | $30.1M | $24.9M | $25.8M | $6.1M | $15.0M | $58.0M | $91.6M | $70.9M | $56.8M | $64.9M |
| Operating Income | -$30.3M | -$24.9M | -$30.1M | -$14.2M | -$21.3M | -$58.0M | -$89.1M | -$65.5M | -$54.8M | -$62.9M |
| EBITDA | -$11.4M | -$24.9M | -$14.4M | -$14.1M | -$14.2M | -$58.1M | -$86.3M | -$62.4M | -$52.1M | -$60.3M |
| Interest Expense | -$60000 | $134000 | $163000 | $1.8M | $720963 | $79000 | 0 | 0 | 0 | $5.2M |
| Pre-tax Income | -$16.2M | -$26.4M | -$8.6M | -$20.2M | -$21.8M | -$58.4M | -$86.8M | -$63.1M | -$54.1M | -$67.8M |
| Income Tax | 0 | -$186000 | -$15.8M | 0 | 0 | -$52000 | 0 | 0 | 0 | 0 |
| Net Income | -$16.2M | -$26.4M | -$8.6M | -$20.2M | -$21.8M | -$58.4M | -$86.8M | -$63.1M | -$54.1M | -$67.8M |
| EPS | $-68.21 | $-69.91 | $-13.98 | $-1.53 | $-0.31 | $-0.30 | $-0.40 | $-0.26 | $-0.20 | $-0.23 |
| EPS (Diluted) | $-67.58 | $-69.91 | $-13.98 | $-1.53 | $-0.31 | $-0.30 | $-0.40 | $-0.26 | $-0.20 | $-0.23 |
| Shares Outstanding (Diluted) | $239824 | $377837 | $618182 | $13.9M | $112.2M | $195.0M | $214.6M | $244.3M | $271.0M | $300.2M |
Price
| Price | $1.00 |
| Market Cap | $339M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explore sector: Healthcare · Biotechnology
More sections of OCGN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks